Search results
The 'Impressive' Results That Sent Top 1% Avidity Biosciences To A Record
Investor's Business Daily· 6 days agoAvidity Biosciences unveiled "impressive" results from a study of its treatment for a rare form of ...
Pfizer 'can't rule out' layoffs in North Carolina after gene therapy flub - Triangle Business...
The Business Journals· 8 hours agoLayoffs could by on the way at Pfizer's massive facility in Sanford after the company's gene therapy...
FDA approves generic Emflaza oral suspension for Duchenne muscular dystrophy
Medical Xpress· 2 days agoThe U.S. Food and Drug Administration has approved the first generic version of Emflaza...
Pfizer Failure in Duchenne Muscular Dystrophy Trial Leaves Field Open for a Rival
Barrons.com· 5 days agoSECTORFOCUS BLOG A second failure of a late-stage trial testing a gene therapy to treat Duchenne ...
Avidity drug for muscular dystrophy shows promise; Syntis takes new approach to weight loss
BioPharma Dive via Yahoo Finance· 7 days agoStudy results indicated Avidity’s medicine muted target genes. Elsewhere, Syntis revealed obesity...
Pfizer's gene-therapy trial failure boosts Sarepta's stock
Morningstar· 6 days agoShares of Sarepta Therapeutics Inc. (SRPT) gained 4% premarket on Thursday after a potential competitor to its gene therapy stumbled in a late-stage trial. Pfizer Inc. said late Wednesday that ...
$10,000 for 10 years: Chesterfield-based organization helping those with neuromuscular disorders
WRIC 8 News Richmond· 6 days agoFor ten years, the Colorado Fund for Muscular Dystrophy (CMFD) has been working to improve the lives...
Pfizer Provides Update on Phase 3 Study of Investigational Gene Therapy for Ambulatory Boys with...
Morningstar· 6 days agoThe primary endpoint in the final analysis was assessed by change in the North Star Ambulatory...
Sarepta’s stock gains after Pfizer’s Duchenne trial failure - Boston Business Journal
The Business Journals· 6 days agoSarepta Therapeutics, a Cambridge drugmaker known for its Duchenne muscular dystrophy treatments,...
Early data for Avidity's RNA therapy show possible functional benefit in muscular dystrophy
FierceBiotech· 7 days agoAvidity Biosciences’ AOC 1020, newly dubbed del-brax, demonstrated a safe profile and was tied to...